NVS Operating Expenses

Novartis AG Common Stock · Operating Expenses

NVS logo

NVS Operating Expenses

Latest reported$24.42B
NVS TTM Operating Expenses ($18.76B → $24.42B)
High-resolution chart · PNG

NVS operating expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Novartis AG Common Stock Operating Expenses — Trailing twelve months (TTM) (USD)
Period endingOperating Expenses (USD)
24,422,634,000
25,070,523,000
24,970,523,000
25,402,000,000
25,395,000,000
24,430,000,000
24,351,000,000
23,819,000,000
24,721,000,000
24,632,000,000
24,419,000,000
25,312,000,000
24,182,000,000
25,692,000,000
26,360,000,000
26,279,000,000
26,392,000,000
25,187,000,000
25,321,000,000
24,506,000,000
24,683,000,000
24,623,000,000
24,625,000,000
25,357,000,000
25,332,000,000
25,446,000,000
25,166,000,000
25,704,000,000
25,040,000,000
24,749,000,000
24,128,000,000
23,294,000,000
23,622,000,000
23,914,000,000
24,331,000,000
24,388,000,000
24,080,000,000
24,259,000,000
23,648,000,000
23,564,000,000
23,723,000,000
23,716,000,000
24,006,000,000
24,015,000,000
24,292,000,000
24,551,000,000
25,200,000,000
26,291,000,000
26,373,000,000
26,146,000,000
26,764,000,000
26,586,000,000
26,880,000,000
27,543,000,000
27,532,000,000
28,593,000,000
29,372,000,000
29,731,000,000
29,394,000,000
28,306,000,000
27,582,000,000
26,154,000,000
25,547,000,000
24,915,000,000
23,897,000,000
23,697,000,000
22,719,000,000
21,712,000,000
21,833,000,000
21,872,000,000
22,181,000,000
23,198,000,000
22,266,000,000
21,347,000,000
20,818,000,000
19,173,000,000
18,947,000,000
18,328,000,000
17,687,000,000
17,229,000,000
16,864,000,000
16,855,000,000
16,753,000,000
16,167,000,000
15,743,000,000
15,282,000,000
15,083,000,000
14,437,000,000
13,951,000,000
13,683,000,000
13,081,000,000
13,722,000,000
13,087,000,000
12,629,000,000
14,480,000,000
15,461,000,000
18,431,000,000
17,853,000,000
17,435,000,000
18,258,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.